Showing 1 - 15 results of 15 for search 'Chongqing Tan', query time: 0.07s Refine Results
  1. 1
    Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China

    Cost-Effectiveness of Domestic PD-1 Inhibitor Camrelizumab Combined With Chemotherapy in the First-Line Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer in China by Liu Qiao, Zhen Zhou, Xiaohui Zeng, Chongqing Tan

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma

    Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients Wit... by Haixia Zhang, Xiaohui Zeng, Ye Peng, Chongqing Tan, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis

    Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis by Xiaohui Zeng, Qiao Liu, Chongqing Tan, Xiaomin Wan, Yunhua Wang, Xiaowei Ma

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis

    Dynamic zero-COVID strategy in controlling COVID-19 in Shanghai, China: A cost-effectiveness analysis by Chongqing Tan, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Lidan Yi, Qiao Liu

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China

    Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China by Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  6. 6
    Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

    Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China by Dongchu Zhou, Xia Luo, Zhen Zhou, Xiaohui Zeng, Xiaomin Wan, Chongqing Tan, Qiao Liu

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  7. 7
    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer

    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  8. 8
    Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review

    Economic Evaluation of Dapagliflozin in the Treatment of Patients With Heart Failure: A Systematic Review by Meiyu Wu, Meiyu Wu, Shuxia Qin, Shuxia Qin, Liting Wang, Liting Wang, Chongqing Tan, Chongqing Tan, Ye Peng, Ye Peng, Xiaohui Zeng, Xia Luo, Xia Luo, Lidan Yi, Lidan Yi, Xiaomin Wan, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  9. 9
    First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis

    First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  10. 10
    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

    Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50% by Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  11. 11
    Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer

    Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell L... by Xia Luo, Qiao Liu, Zhen Zhou, Lidan Yi, Liubao Peng, Xiaomin Wan, Xiaohui Zeng, Chongqing Tan, Sini Li

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  12. 12
    Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study

    Benefit-to-harm ratio and cost-effectiveness of government-recommended gastric cancer screening in China: A modeling study by Shuxia Qin, Xuehong Wang, Sini Li, Sini Li, Chongqing Tan, Xiaohui Zeng, Meiyu Wu, Ye Peng, Liting Wang, Xiaomin Wan

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  13. 13
    Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

    Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer by Xiaomin Wan, Xiaohui Zeng, Liubao Peng, Ye Peng, Qiao Liu, Lidan Yi, Xia Luo, Qijian Deng, Qijian Deng, Chongqing Tan

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  14. 14
    Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

    Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis by Ye Peng, Xiaohui Zeng, Liubao Peng, Qiao Liu, Lidan Yi, Xia Luo, Sini Li, Liting Wang, Shuxia Qin, Xiaomin Wan, Chongqing Tan

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  15. 15
    Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China

    Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China by Li Zeng, Li Zeng, Huihui Chen, Huihui Chen, Heng Xiang, Mengru Zeng, Mengru Zeng, Mi Zhou, Mi Zhou, Chongqing Tan, Hong Liu, Hong Liu, Guochun Chen, Guochun Chen, Guochun Chen

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: